Paris, France

Nicolas Dupin


 

Average Co-Inventor Count = 4.0

ph-index = 1


Location History:

  • Colombes, FR (2019)
  • Paris, FR (2020 - 2023)

Company Filing History:


Years Active: 2019-2023

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Nicolas Dupin

Introduction

Nicolas Dupin is a notable inventor based in Paris, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds aimed at treating inflammatory disorders. With a total of 4 patents to his name, Dupin's work is recognized for its potential impact on various skin conditions.

Latest Patents

Dupin's latest patents focus on Meclozine derivatives and diclazuril derivatives. These compounds are designed for use in the prevention and treatment of disorders associated with inflammation. Specifically, his inventions target conditions such as acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis, and atopic dermatitis. The compounds are presented in a general formula, which includes pharmaceutically acceptable salts and/or solvates.

Career Highlights

Throughout his career, Nicolas Dupin has worked with prestigious institutions, including Assistance Publique-Hôpitaux de Paris and Université de Paris. His research and innovations have contributed to advancements in medical treatments, particularly in dermatology.

Collaborations

Dupin has collaborated with notable colleagues, including Vincent Calvez and Philippe Grange. These partnerships have further enhanced his research and development efforts in the pharmaceutical field.

Conclusion

Nicolas Dupin's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to improving treatments for inflammatory disorders. His work continues to influence the medical community and offers hope for patients suffering from various skin conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…